T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients

Detalles Bibliográficos
Autores principales: Heitz, Jade, Razanamahery, Jerome, Audia, Sylvain, Bour, Jean-Baptiste, Guy, Julien, Berthier, Sabine, Leguy, Vanessa, Ghesquiere, Thibault, Nicolas, Barbara, Samson, Maxime, Bonnotte, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784462/
https://www.ncbi.nlm.nih.gov/pubmed/35094894
http://dx.doi.org/10.1016/j.ejim.2022.01.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784462/
https://www.ncbi.nlm.nih.gov/pubmed/35094894
http://dx.doi.org/10.1016/j.ejim.2022.01.030

Ejemplares similares